Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(4.18)
# 480
Out of 4,670 analysts
40
Total ratings
47.5%
Success rate
18.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANNX Annexon | Reiterates: Overweight | n/a | $5.14 | - | 9 | Nov 15, 2024 | |
| VSTM Verastem | Reiterates: Overweight | n/a | $4.00 | - | 1 | Oct 18, 2024 | |
| VERA Vera Therapeutics | Reiterates: Overweight | $107 | $48.31 | +121.49% | 7 | Oct 3, 2024 | |
| PLRX Pliant Therapeutics | Reiterates: Overweight | n/a | $12.98 | - | 4 | Aug 8, 2024 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Overweight | n/a | $16.91 | - | 4 | Aug 6, 2024 | |
| ALEC Alector | Reiterates: Overweight | n/a | $3.94 | - | 4 | Jul 29, 2024 | |
| DNTH Dianthus Therapeutics | Initiates: Overweight | n/a | $22.34 | - | 1 | Jun 27, 2024 | |
| JSPR Jasper Therapeutics | Reiterates: Overweight | n/a | $22.05 | - | 4 | Jun 18, 2024 | |
| RZLT Rezolute | Reiterates: Overweight | $5 | $4.91 | +1.83% | 3 | Sep 19, 2023 | |
| ABOS Acumen Pharmaceuticals | Reiterates: Overweight | $13 | $2.37 | +448.52% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $9.82 | -18.53% | 1 | Mar 20, 2023 |
Annexon
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.14
Upside: -
Verastem
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.00
Upside: -
Vera Therapeutics
Oct 3, 2024
Reiterates: Overweight
Price Target: $107
Current: $48.31
Upside: +121.49%
Pliant Therapeutics
Aug 8, 2024
Reiterates: Overweight
Price Target: n/a
Current: $12.98
Upside: -
Arcturus Therapeutics Holdings
Aug 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.91
Upside: -
Alector
Jul 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.94
Upside: -
Dianthus Therapeutics
Jun 27, 2024
Initiates: Overweight
Price Target: n/a
Current: $22.34
Upside: -
Jasper Therapeutics
Jun 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $22.05
Upside: -
Rezolute
Sep 19, 2023
Reiterates: Overweight
Price Target: $5
Current: $4.91
Upside: +1.83%
Acumen Pharmaceuticals
Jul 17, 2023
Reiterates: Overweight
Price Target: $13
Current: $2.37
Upside: +448.52%
Mar 20, 2023
Reiterates: Overweight
Price Target: $8
Current: $9.82
Upside: -18.53%